- Home
- VYNE vs ATHA Comparison
VYNE vs ATHA Comparison
Compare VYNE & ATHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VYNE
- ATHA
- Stock Information
- Founded
- VYNE 2003
- ATHA 2011
- Country
- VYNE United States
- ATHA United States
- Employees
- VYNE N/A
- ATHA N/A
- Industry
- VYNE Biotechnology: Pharmaceutical Preparations
- ATHA Medicinal Chemicals and Botanical Products
- Sector
- VYNE Health Care
- ATHA Health Care
- Exchange
- VYNE Nasdaq
- ATHA Nasdaq
- Market Cap
- VYNE 16.0M
- ATHA 15.7M
- IPO Year
- VYNE 2018
- ATHA 2020
- Fundamental
- Price
- VYNE $1.46
- ATHA $0.46
- Analyst Decision
- VYNE Strong Buy
- ATHA Buy
- Analyst Count
- VYNE 2
- ATHA 4
- Target Price
- VYNE $6.25
- ATHA $11.25
- AVG Volume (30 Days)
- VYNE 895.6K
- ATHA 282.4K
- Earning Date
- VYNE 08-13-2025
- ATHA 08-04-2025
- Dividend Yield
- VYNE N/A
- ATHA N/A
- EPS Growth
- VYNE N/A
- ATHA N/A
- EPS
- VYNE N/A
- ATHA N/A
- Revenue
- VYNE $605,000.00
- ATHA N/A
- Revenue This Year
- VYNE $42.51
- ATHA N/A
- Revenue Next Year
- VYNE N/A
- ATHA N/A
- P/E Ratio
- VYNE N/A
- ATHA N/A
- Revenue Growth
- VYNE 43.03
- ATHA N/A
- 52 Week Low
- VYNE $0.85
- ATHA $0.22
- 52 Week High
- VYNE $4.30
- ATHA $3.67
- Technical
- Relative Strength Index (RSI)
- VYNE 56.57
- ATHA 65.56
- Support Level
- VYNE $1.10
- ATHA $0.44
- Resistance Level
- VYNE $1.49
- ATHA $0.51
- Average True Range (ATR)
- VYNE 0.15
- ATHA 0.05
- MACD
- VYNE -0.00
- ATHA 0.01
- Stochastic Oscillator
- VYNE 90.45
- ATHA 72.32
About VYNE VYNE Therapeutics Inc.
VYNE Therapeutics Inc is a biopharmaceutical company focused on developing proprietary, innovative and differentiated therapies for the treatment of immuno-inflammatory conditions. Its advanced product candidate is FMX114, which is being evaluated for the potential treatment of mild-to-moderate AD (atopic dermatitis). The company is also in the pre-clinical stages of developing products containing BET (Bromodomain and Extra-Terminal Domain) inhibitor compounds. Its products include AMZEEQ, ZILXI, and FCD105.
About ATHA Athira Pharma Inc.
Athira Pharma Inc is a late clinical-stage biopharmaceutical company focused on developing small molecules engineered to restore neuronal health and slow neurodegeneration. Its pipeline candidates are; Fosgonimeton (ATH-1017) is a small molecule drug candidate designed to enhance the activity of the neurotrophic hepatocyte growth factor (HGF) system; ATH-1020 a novel, orally available, next-generation small molecule drug candidate designed to positively modulate the neurotrophic HGF system; ATH-1105 is a novel, orally available, next-generation, small molecule drug candidate designed to positively modulate the neurotrophic HGF system.